A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Multicenter Trial Comparing Two Schedules of GW572016 as First or Second Line Monotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer With Either Bronchioloalveolar Carcinoma or No Smoking History
Sponsor: GlaxoSmithKline
Terminated
Based on interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment was stopped due to lack of efficacy
Other terminated trials from GlaxoSmithKline
Other Lung Cancer, Non-Small Cell trials with similar outcome
This PHASE2 trial investigates Lung Cancer, Non-Small Cell and is currently terminated or withdrawn. GlaxoSmithKline leads this study, which shows 11 recorded versions since 2003 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2
-
May 2017 — Aug 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — May 2017 [monthly]
Terminated PHASE2
First recorded
Nov 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .